Phase 3 Clinical Trials With Primary Completion Dates in August 2019
This is a list of Phase 3 trials with primary completion dates in August 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Primary Completion Date
|ACADIA Pharmaceuticals Inc.
|Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
|Acasti Pharma, Inc.
|A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
|A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
|Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
|Catalyst Pharmaceuticals, Inc.
|Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
|Eagle Pharmaceuticals, Inc.
|Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
|Karyopharm Therapeutics Inc.
|Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer.
|Intec Pharma Ltd.
|A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
|An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
|Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
|Teva Pharmaceutical Industries Limited
|Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma